Stock Yards Bank & Trust Co. Has $17.39 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Stock Yards Bank & Trust Co. reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 10.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 89,028 shares of the company’s stock after selling 10,684 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Zoetis were worth $17,394,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Asset Dedication LLC boosted its position in shares of Zoetis by 4.8% in the 2nd quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock worth $204,000 after purchasing an additional 54 shares during the last quarter. Cherry Creek Investment Advisors Inc. raised its position in shares of Zoetis by 2.0% in the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock valued at $590,000 after acquiring an additional 58 shares during the period. L. Roy Papp & Associates LLP boosted its stake in Zoetis by 2.8% during the 2nd quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock worth $385,000 after acquiring an additional 60 shares during the last quarter. Grove Bank & Trust raised its holdings in Zoetis by 0.5% in the third quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock worth $2,298,000 after purchasing an additional 61 shares during the period. Finally, Hancock Whitney Corp boosted its position in shares of Zoetis by 0.3% during the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock worth $3,628,000 after purchasing an additional 61 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.3 %

Shares of ZTS stock opened at $177.17 on Thursday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company has a market capitalization of $79.93 billion, a PE ratio of 33.30, a price-to-earnings-growth ratio of 2.89 and a beta of 0.89. The firm has a 50 day moving average price of $181.06 and a two-hundred day moving average price of $181.14. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last announced its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.36 EPS. As a group, analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st were paid a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date was Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Analysts Set New Price Targets

Several research firms have weighed in on ZTS. Stifel Nicolaus lifted their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Piper Sandler boosted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. UBS Group began coverage on Zoetis in a report on Monday. They set a “neutral” rating and a $196.00 target price for the company. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and a consensus target price of $216.70.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.